ARISTO PHARMACEUTICALS PRIVATE LIMITED
Company's authorized capital stands at Rs 99.0 lakhs and has 99.969696% paid-up capital which is Rs 98.97 lakhs. Aristo Pharmaceuticals Private Limited last annual general meet (AGM) happened on 21 Sep, 2017. The company last updated its financials on 31 Mar, 2017 as per Ministry of Corporate Affairs (MCA).
Aristo Pharmaceuticals Private Limited is majorly in Manufacturing (Metals & Chemicals, and products thereof) business from last 53 years and currently, company operations are active. Current board members & directors are RANDHIR KUMAR BACHAN, UMESH SHARMA, VIRENDRA SHARMA and RAJ NANDAN SHARMA .
Company is registered in Mumbai (Maharashtra) Registrar Office. Aristo Pharmaceuticals Private Limited registered address is 12 J N HEREDIA MARGBALLARD ESTATE MUMBAI MH 400001 IN.
Aristo Pharmaceuticals Private Limited Details
| CIN | U24239MH1971PTC015425 |
| Date of Incorporation | 08 Nov, 1971 |
| Status | Active |
| Company Category | Company limited by Shares |
| Company Sub-category | Non-govt company |
| Company Class | Private |
| Business Activity | Manufacturing (Metals & Chemicals, and products thereof) |
| Authorized Capital | 99.0 lakhs |
| Paid-up Capital | 98.97 lakhs |
| Paid-up Capital % | 99.969696 |
| Registrar Office City | Mumbai |
| Registered State | Maharashtra |
| Registration Number | 15425 |
| Registration Date | 08 Nov, 1971 |
| Listing Status | Unlisted |
| AGM last held on | 21 Sep, 2017 |
| Balance Sheet last updated on | 31 Mar, 2017 |
Aristo Pharmaceuticals Private Limited News
Earnings outlook for Nifty flat; ICICI Bank, L&T could give 17-19% returns post Q2 results
Technology companies outperformed expectations, achieving solid revenue growth while expressing cautious optimism for the coming quarters. The healthcare sector showed strong performance, with stable growth in domestic formulations. This earnings season has reinforced the importance of selectively positioning within growth-oriented sectors.
Novartis CEO 'very confident' on sales target, doesn't fear patent cliff
Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday.
Suven, Cohance aim to double combined business revenue to Rs 6,000 cr by FY29
Suven Pharmaceuticals and Cohance Lifesciences plan to merge and aim to double their revenue to Rs 6,000 crore by FY29 through organic and inorganic growth. The merger has received NSE and BSE approvals, with a shareholders meeting scheduled for November 28, 2024. The combined entity will focus on pharma CDMO, specialty chemicals CDMO, and APIs.
Gland Pharma appoints Shyamakant Giri as new CEO
Shyamakant Giri has been appointed as the new CEO of Gland Pharma, effective January 15, 2025. Giri brings over 25 years of experience in the pharmaceutical and healthcare sectors. The current CEO, Srinivas Sadu, will remain as the executive chairman to support the company's growth trajectory.
Overweight on Lupin, target price Rs 2,500: Axis Securities
Axis Securities has overweight call on Lupin with a target price of Rs 2,500. The current market price of Lupin is Rs 2,216.
* Ministry of Corporate Affairs, 2019, Company/LLP Data, (Government of India administrative body to govern and regulate corporate affairs through the Companies Act 1956 & 2013 including other allied Acts, Bills and Rules) http://www.mca.gov.in/, Updated as on 04 Dec, 2018.
Please Note: Data on this page may not be updated vis-à-vis company’s current credentials.
